PEDIATRICS Vol. 36 No. 3 September 1965, pp. 322-335
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Whitten, C. F.
Right arrow Articles by Brough, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Whitten, C. F.
Right arrow Articles by Brough, A. J.

STUDIES IN ACUTE IRON POISONING. I. DESFERRIOXAMINE IN THE TREATMENT OF ACUTE IRON POISONING: CLINICAL OBSERVATIONS, EXPERIMENTAL STUDIES, AND THEORETICAL CONSIDERATIONS

Charles F. Whitten M.D.1, George W. Gibson M.S.1, Mary H. Good B.S.1, Jesse F. Goodwin Ph.D.1, and A. Joseph Brough M.D.1

1 Department of Pediatrics of the Children's Hospital of Michigan and the Departments of Biochemistry and Pathology, Wayne State University School of Medicine

1. Thirteen children who had ingested iron salts were treated with a combination of enteral and parenteral Desferrioxamine. Although all recovered, a review of the literature indicates that criteria are not available to determine whether the treatment was responsible for their survival.

2. Three of 9 dogs recovered when treated with enteral and intravenous [See Table XII. in Source Pdf.] Desferrioxamine, which was started 1 hour after the administration of a L D.100 dose of ferrous sulfate.

3. Desferrioxamine does not prevent the absorption of the quantities of iron involved in acute iron poisoning.

4. Further studies are essential to: (a) establish criteria for determining the quantity of Desferrioxamine to use in individual cases so that maximum effectiveness will be achieved without producing serious toxicity, and (b) to determine whether toxicity from the iron-desferrioxamine complex can be prevented.

Submitted on December 2, 1964
Accepted on March 21, 1965




This article has been cited by other articles:


Home page
 BloodHome page
R. J. Bergeron, J. Wiegand, and G. M. Brittenham
HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning
Blood, April 15, 2002; 99(8): 3019 - 3026.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. N. Cohen
Studies in Acute Iron Poisoning. I. Desferrioxamine in the Treatment of Acute Iron Poisoning: Clinical Observations, Experimental Studies, and Theoretical Considerations, by Charles F. Whitten et al, Pediatrics, 1965;36:322-335; and Studies in Acute Iron Poisoning. II. Further Observations on Desferrioxamine in the Treatment of Acute Experimental Iron Poisoning, by Charles F. Whitten et al, Pediatrics, 1966;38:102-110
Pediatrics, July 1, 1998; 102(1): 241 - 243.
[Abstract] [Full Text]

Home page
 J Biomater ApplHome page
J. A. Braatz
Biocompatible Polyurethane-Based Hydrogel
J Biomater Appl, January 1, 1994; 9(1): 71 - 96.
[PDF]

Home page
 CLIN PEDIATRHome page
D. J. Greenblatt, M. D. Allen, and J. Koch-Weser
Accidental Iron Poisoning in Childhood: Six Cases Including One Fatality
Clinical Pediatrics, September 1, 1976; 15(9): 835 - 838.
[Abstract] [PDF]

Home page
 CLIN PEDIATRHome page
W. F. Westlin
Deferoxamine in the Treatment of Acute Iron Poisoning: Clinical Experiences with 172 Children
Clinical Pediatrics, September 1, 1966; 5(9): 531 - 535.
[PDF]

Home page
 CLIN PEDIATRHome page
R. McDonald
Chelating Agents in Chronic Iron Overload
Clinical Pediatrics, August 1, 1966; 5(8): 457 - 459.
[PDF]